A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
about
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalNotch Signaling in Neuroendocrine TumorsSmall cell lung cancer (SCLC): no treatment advances in recent yearsCellular and molecular biology of small cell lung cancer: an overviewTargeting angiogenesis in small cell lung cancerZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expressionChemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug ConjugatesNeuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineeringSelective gene expression analysis of the neuroepithelial body microenvironment in postnatal lungs with special interest for potential stem cell characteristics.Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targetsSmall Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).Research progress in the treatment of small cell lung cancer.Role of tumor microenvironment in tumorigenesis.What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016.Synthesis, DNA binding affinity and anticancer activity of novel 4H-benzo[g][1,2,3]triazolo[5,1-c][1,4]oxazocines.Unravelling the biology of SCLC: implications for therapy.Ganetespib for small cell lung cancer.Prospects and progress of antibody-drug conjugates in solid tumor therapies.MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Strategies and challenges for the next generation of antibody-drug conjugates.Emerging Variants of Castration-Resistant Prostate Cancer.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.Update in Lung Cancer 2015.Targeting the seeds of small cell lung cancerEmerging strategies for the treatment of advanced small cell lung cancer.ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.Major milestones in translational oncology.Unraveling the genomic complexity of small cell lung cancer.Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.Toppling high-grade pulmonary neuroendocrine tumors with a DLL3-targeted trojan horse.Relevance of genetic alterations in squamous and small cell lung cancer.Venetoclax is effective in small cell lung cancers with high BCL-2 expression.Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates.Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.
P2860
Q26744536-6F11B632-AD33-4EC4-8139-34A2E96768B2Q26752380-C6BE8F9E-7AAD-47CC-8B2E-675F63532AB7Q26767020-25C75C6E-E949-49D5-9EEA-DC528FAFE437Q26767029-29CBC30B-971C-4B99-B130-436AAEA548A3Q28068385-93A70E9E-5752-4A04-9A74-2ABB01E3E73AQ28602015-1892F0AC-8CCA-42C9-9B90-7F986748C9D2Q28828981-4954128A-5C82-4A78-B459-0E3F8CC6078CQ30238552-8F04C131-4195-4512-B441-F647694F4DF1Q33437481-E4F66F29-A77D-4AA4-975E-D78CE7C2C73AQ33587970-FF480B4A-8E9B-4EC0-A81E-CA63724799D3Q33651475-04A74B70-071D-467F-A6B4-B54B9F1FA6BFQ36270042-4E5F98F3-C51B-48CB-AE7A-F6C09E2F9D0BQ36811784-E2CE96C8-AE16-4BAC-A21B-53F0BC15717FQ37561359-2CC5B989-8847-43F6-AE0B-4C90DF37E156Q37604301-77A0654B-44F5-4780-AC57-9027D2E6E56BQ37738074-75596B78-6AEF-477A-A4F1-DAA6D0B24BDAQ38661479-194419F2-096A-42A4-AB38-46F8718D9685Q38742130-1BE8CB31-EDC7-4F43-937C-BCD996698AE0Q38769421-EA9BAE81-780E-44D2-8F98-6F23BFDF95B3Q38786678-0182B063-FE3A-4714-992E-29F0CCB98153Q38798525-684B1CF7-DFAF-4145-A510-BB08AA8D7CC5Q39019412-8BA2D6D0-D96A-40BC-8BD4-9234937976CCQ39182945-927800B8-5C53-4574-93BB-99B0649BE369Q39210257-2CE865C1-AF54-4A87-AAFB-EBE08309E643Q39210427-30405D29-3106-4352-835A-D1BBF8CA9043Q39393217-BD45624C-A9A2-4464-A94A-2577154489C5Q40208474-77263CFB-7592-47D3-900E-7C378E95FCD8Q41115829-47F4C6E1-ED83-4F31-AC57-FDEADA2AEA92Q42314900-19450C3F-40A2-48CE-B827-60949289D258Q42369314-909A1B73-C0E3-447E-AB95-8C47A478B2D7Q42382121-F9BAAE4A-C131-4A9B-AA1D-695285AC7A96Q42398020-7D990BD7-E804-4D51-B0A3-96FF3B333F34Q42398708-1F21EA67-F0CC-45BB-ACC6-29DE7CC573D7Q42408728-645FF59F-A7E9-4A67-BAF7-88106AEC62F6Q42623025-A472AC31-9E5D-4C21-BDD7-AE6E09F2AE46Q44483486-719D9BAE-CE4C-44F0-A411-AE7BC0C76D9CQ45072361-1ECC93DC-0807-4D94-9D85-939824CE0804Q46352637-591A7882-E3BC-4B27-A4CC-1276038B53C2Q47120183-2C9A5E95-3C63-4982-BBA9-4879E31C00E3Q47139670-67B08318-3901-4709-B652-6D2B04A07AF0
P2860
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@ast
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@en
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@nl
type
label
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@ast
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@en
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@nl
prefLabel
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@ast
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@en
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@nl
P2093
P2860
P50
P1476
A DLL3-targeted antibody-drug ...... tumor-initiating cells in vivo
@en
P2093
Afshin Dowlati
Albert Park
Amy Laysang
Andrzej Badzio
Brian Slingerland
David H Harpole
J T Poirier
Javier Lopez-Molina
P2860
P304
P356
10.1126/SCITRANSLMED.AAC9459
P407
P577
2015-08-01T00:00:00Z